Insider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Acquires $11,064.00 in Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock in a transaction dated Tuesday, May 12th. The shares were purchased at an average price of $13.83 per share, with a total value of $11,064.00. Following the completion of the acquisition, the insider owned 830,584 shares in the company, valued at $11,486,976.72. The trade was a 0.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Friday, May 15th, Adar1 Capital Management, Llc purchased 300 shares of Rallybio stock. The shares were purchased at an average price of $13.90 per share, with a total value of $4,170.00.
• On Wednesday, May 13th, Adar1 Capital Management, Llc purchased 79,259 shares of Rallybio stock. The shares were purchased at an average price of $13.99 per share, with a total value of $1,108,833.41.
• On Monday, May 11th, Adar1 Capital Management, Llc purchased 50,000 shares of Rallybio stock. The shares were purchased at an average price of $14.00 per share, with a total value of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock. The shares were purchased at an average price of $14.00 per share, with a total value of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The shares were purchased at an average price of $13.97 per share, with a total value of $1,687,631.88.

Rallybio Price Performance

Shares of Rallybio stock opened at $14.30 on Friday. The firm has a market cap of $75.65 million, a price-to-earnings ratio of -3.14 and a beta of -1.10. Rallybio Corporation has a 52-week low of $2.16 and a 52-week high of $15.31. The stock has a 50-day simple moving average of $9.84 and a 200-day simple moving average of $7.05.

Rallybio (NASDAQ:RLYB) last posted its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.26). Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.21 million.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its holdings in shares of Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after buying an additional 120,892 shares during the last quarter. Citadel Advisors LLC lifted its holdings in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares during the last quarter. Susquehanna International Group LLP lifted its holdings in shares of Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after buying an additional 113,031 shares during the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after buying an additional 38,205 shares during the last quarter. 90.34% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on RLYB shares. Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a report on Friday, May 8th. Wall Street Zen upgraded Rallybio to a “hold” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.